- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndrome
- Interventions
- Bortezomib, Tacrolimus, Methotrexate
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 446
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Leukemia, Acute Myeloid, Leukemia, Lymphoblastic,Acute, Myelodysplastic Syndromes
- Interventions
- brentuximab vedotin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Gastric Cancer, Head and Neck Cancer, Lymphoma, Lymphoproliferative Disorder
- Interventions
- oral sodium phenylbutyrate, valganciclovir, polymerase chain reaction, protein expression analysis, biopsy
- Drug · Genetic · Procedure
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Daratumumab/rHuPH20
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2040
- U.S. locations
- 837
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Interventions
- Laboratory Biomarker Analysis, Ruxolitinib Phosphate
- Other · Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Rochester, Minnesota • Omaha, Nebraska
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Multiple Myeloma
- Interventions
- Dynamic contrast-enhanced computed tomography, Ioversol
- Radiation · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hematologic Diseases, Leukemia, Lymphoma, Myeloma
- Interventions
- Busulfan, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 6 Months to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
- Interventions
- CD19CAR/virus specific T cells, Benadryl and Tylenol
- Genetic · Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2031
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, Breakpoint Cluster Region-abl Translocation (BCR-ABL) Negative, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Gastrointestinal Complications, Juvenile Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Previously Treated Childhood Rhabdomyosarcoma, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Small Lymphocytic Lymphoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Breast Cancer, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Ovarian Epithelial Cancer, Stage IV Small Lymphocytic Lymphoma
- Interventions
- lithium carbonate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Secondary Myelodysplastic Syndrome
- Interventions
- Busulfan, Cyclophosphamide, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis, Melphalan Hydrochloride, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus, Total-Body Irradiation
- Drug · Procedure · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 5 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, HDT-AHCT
- Interventions
- Romiplostim
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Non-Hodgkin Lymphoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Carmustine, Cytarabine, Etoposide, Melphalan, Rituximab, Vorinostat
- Procedure · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
- Interventions
- Ixazomib Citrate, Lenalidomide, Questionnaire Administration
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Hodgkins Lymphoma, Non-Hodgkins Lymphoma
- Interventions
- Allogeneic stem cell transplant
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Lymphocytic Leukemia
- Interventions
- CART-19
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- T Cell Lymphoma
- Interventions
- Brentuximab Vedotin
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Haploidentical Stem Cell Transplantation
- Drug · Other
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 16 Years to 90 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Multiple Myeloma, Leukemia, Plasma Cell
- Interventions
- Carfilzomib, Melphalan, Filgrastim
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- chemotherapy, total-body irradiation, peripheral blood stem cell transplantation, cyclosporine, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, therapeutic allogeneic lymphocytes
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 50 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 3
- States / cities
- Duarte, California • Stanford, California • Seattle, Washington
- Conditions
- Multiple Myeloma
- Interventions
- Autologous Stem Cell Transplant, Melphalan, Lenalidomide, MK-3475
- Procedure · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Milwaukee, Wisconsin
- Conditions
- Leukemia, Lymphoma
- Interventions
- Pentostatin, Tacrolimus, Methotrexate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer
- Interventions
- fatigue assessment and management, management of therapy complications, psychosocial assessment and care
- Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 9
- States / cities
- Stanford, California • Denver, Colorado • Gainesville, Florida + 5 more
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm
- Interventions
- lenalidomide, vorinostat
- Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- Columbus, Ohio